12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Simponi golimumab: Additional Phase III data

Additional data from the double-blind, international Phase III GO-FURTHER trial in 592 patients with active moderate to severe RA despite methotrexate treatment showed that 2 mg/kg IV Simponi given at weeks 0 and 4 and then every 8 weeks plus methotrexate significantly reduced mean van der Heijde-Sharp (vdH-S) score, an x-ray measure of joint destruction, from baseline to week 24 vs. placebo (0.03 vs. 1.09 points, p<0.001). At week 52, IV Simponi also significantly reduced mean vdH-S score from...

Read the full 385 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >